Molly Cogan - NRx Pharmaceuticals Sr Affairs
| NRXPW Stock | USD 0.05 0 3.73% |
Insider
Molly Cogan is Sr Affairs of NRx Pharmaceuticals
| Address | 1201 Orange Street, Wilmington, DE, United States, 19801 |
| Phone | (484) 254-6134 |
| Web | https://www.nrxpharma.com |
NRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.1597) % which means that it has lost $1.1597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.8261) %, meaning that it generated substantial loss on money invested by shareholders. NRx Pharmaceuticals' management efficiency ratios could be used to measure how well NRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NRx Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 2.70 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (3.92). At this time, NRx Pharmaceuticals' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 409.4 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert MIM | NRX Pharmaceuticals | 58 | |
| Jack MBA | Relief Therapeutics Holding | 67 | |
| Todd Rearick | Quantum Si incorporated | N/A | |
| Christian Lapointe | Quantum Si incorporated | 53 | |
| Matthew Dyer | Quantum Si incorporated | 43 | |
| Michael MD | Quantum Si incorporated | 40 | |
| Serene MPH | Relief Therapeutics Holding | N/A | |
| John Stark | Quantum Si incorporated | 50 | |
| Claudia Drayton | Quantum Si incorporated | 56 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Dorian Bevec | Relief Therapeutics Holding | 65 | |
| Anthony Kim | Relief Therapeutics Holding | 51 | |
| Marc Cantillon | Reviva Pharmaceuticals Holdings | 66 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Jack Weinstein | Relief Therapeutics Holding | 66 | |
| Dennis McBride | NRX Pharmaceuticals | N/A | |
| DPhil MBA | Relief Therapeutics Holding | 60 | |
| Seth Voorhees | NRX Pharmaceuticals | 63 | |
| Paolo Galfetti | Relief Therapeutics Holding | 57 | |
| Michael Kunz | NRX Pharmaceuticals | 59 | |
| MPH MD | NRX Pharmaceuticals | 67 | |
Management Performance
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 |
NRx Pharmaceuticals Leadership Team
Elected by the shareholders, the NRx Pharmaceuticals' board of directors comprises two types of representatives: NRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NRx. The board's role is to monitor NRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. NRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Suzanne Messere, Investor Relations | ||
| Robert MIM, Chief Operations | ||
| Michael Kunz, Gen Sec | ||
| Stephen Esq, CEO Secretary | ||
| Richard Narido, Principal CFO | ||
| Molly Cogan, Sr Affairs | ||
| Seth Voorhees, CFO Treasurer | ||
| Dennis McBride, Chief Scientist | ||
| Matthew Duffy, Chief Therapeutics | ||
| Prof Javitt, CoFounder Board | ||
| Riccardo Panicucci, Chief Officer | ||
| MPH MD, Chief CoFounder | ||
| Philip Lavin, Chief Methodologist |
NRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Number Of Shares Shorted | 1.47 K | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NRx Stock Analysis
When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.